Meta-analysis is the statistical combination of results from two or more separate studies. Potential advantages of meta-analyses include an increase in power, an improvement in precision, the ability to answer questions not posed by individual studies, and the opportunity to settle controversies arising from conflicting claims. However, they also have the potential to mislead seriously, particularly if specific study designs, within-study biases, variation across studies, and reporting biases are not carefully considered. It is important to be familiar with the type of data (e.g. dichotomous, continuous) that result from measurement of an outcome in an individual study, and to choose suitable effect measures for comparing intervention groups. Most meta-analysis methods are variations on a weighted average of the effect estimates from the different studies. Variation across studies (heterogeneity) must be considered. Random-effects meta-analyses allow for heterogeneity by assuming that underlying effects follow a normal distribution. Various judgments are required in the process of preparing a meta-analysis. Especially, quality assessment of randomized controlled trial is essential. There are several methods to assess the methodological quality of clinical trials, including scales, individual markers, and checklists. Analyzing the quality of studies makes the results of meta-analysis more reliable. Sensitivity analyses should be used to examine whether overall findings are robust to potentially influential decisions.
. Referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots, minimization* Sequence generated by odd or even date of birth, sequence generated by some rule based on date (or day) of admission, sequence generated by some rule based on hospital or clinic record number Allocation concealment
통계분석 및 결과 제시

Yes
No
Central allocation (including telephone, web-based and pharmacy-controlled randomization), sequentially numbered drug containers of identical appearance, sequentially numbered, opaque, sealed envelopes Using an open random allocation schedule(e.g. a list of random numbers), assignment envelopes were used without appropriate safeguards, alternation or rotation, date of birth, case record number, any other explicitly unconcealed procedure Blinding Yes
No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding; Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding; Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken; Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias Incomplete outcome data
Yes
No
No missing outcome data; Reasons for missing outcome data unlikely to be related to true outcome; Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; For continuous outcome data, plausible effect size among missing outcomes not enough to have a clinically relevant impact on observed effect size; Missing data have been imputed using appropriate methods Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; For continuous outcome data, plausible effect size among missing outcomes enough to induce clinically relevant bias in observed effect size; 'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization; Potentially inappropriate application of simple imputation Selective outcome reporting
Yes
No
The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified Not all of the study's pre-specified primary outcomes have been reported; One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g., subscales) that were not pre-specified; One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; The study report fails to include results for a key outcome that would be expected to have been reported for such a study Other potential threats to validity
Yes
No
Had a potential source of bias related to the specific study design used; or Stopped early due to some data-dependent process (including a formal-stopping rule); or Had extreme baseline imbalance; or Has been claimed to have been fraudulent; or Had some other problem Insufficient information to assess whether an important risk of bias exists; or Insufficient rationale or evidence that an identified problem will introduce bias *Minimization may be implemented without a random element, and this is considered to be equivalent to being random.
